RIGL — Rigel Pharmaceuticals, Inc. Stock Price, Chart & AI Report

Positive Aug 6, 2025 • 11:19 UTC The Motley Fool • Jesterai

Rigel (RIGL) Q2 Revenue Jumps 176%

Rigel Pharmaceuticals exceeded Q2 2025 financial expectations with 176.4% revenue growth, driven by strong product sales and a significant Eli Lilly collaboration, raising full-year revenue guidance to $270-$280 million.

RIGL LLY pharmaceuticals earnings revenue drug development oncology

Sentiment note

Significantly beat analyst expectations with 176.4% revenue growth, raised full-year guidance, demonstrated strong product sales across three FDA-approved drugs, and reported substantial net income of $59.6 million

Positive Dec 12, 2024 • 12:30 UTC GlobeNewswire Inc. • N/A

Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique

Knight Therapeutics, a specialty pharmaceutical company, announced that its Mexican subsidiary has obtained regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib) to treat adult patients with chronic immune thrombocytopenia (ITP) whose response to prior treatment was insufficient.

RIGL Knight Therapeutics TAVALISSE chronic immune thrombocytopenia COFEPRIS Mexico

Sentiment note

The article mentions that Knight Therapeutics had previously concluded an agreement with Rigel Pharmaceuticals to obtain the exclusive rights to commercialize fostamatinib in Latin America, which is a positive development for Rigel Pharmaceuticals.

Positive Nov 6, 2024 • 09:59 UTC GlobeNewswire Inc. • Researchandmarkets.Com

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen Pharmaceuticals

The article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.

LEGN TAK CRVS RIGL T-cell lymphoma drug pipeline novel therapies regulatory support

Sentiment note

Rigel Pharmaceuticals is mentioned as one of the key players in the T-cell lymphoma drug pipeline, indicating their contribution to the development of new therapies for this disease.

Unknown May 10, 2024 • 16:00 UTC Zacks Investment Research • Zacks Equity Research

Rigel (RIGL) Upgraded to Buy: Here's What You Should Know

Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

RIGL

Unknown May 7, 2024 • 21:50 UTC Zacks Investment Research • Zacks Equity Research

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -66.67% and 5.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

RIGL MEIP

Unknown May 2, 2024 • 14:01 UTC Zacks Investment Research • Zacks Equity Research

ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRPH RIGL

Unknown Apr 30, 2024 • 21:30 UTC Zacks Investment Research • Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of -34.62% and 33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

LYRA RIGL

Unknown Apr 30, 2024 • 14:01 UTC Zacks Investment Research • Zacks Equity Research

Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RIGL ARDX

Unknown Apr 12, 2024 • 12:21 UTC Zacks Investment Research • Zacks Equity Research

Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?

Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

SLN RIGL

Unknown Mar 5, 2024 • 22:10 UTC Zacks Investment Research • Zacks Equity Research

Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4

Rigel (RIGL) delivered earnings and revenue surprises of 100% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

RIGL AKBA

Unknown Feb 28, 2024 • 13:27 UTC Zacks Investment Research • Zacks Equity Research

OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?

OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OABI RIGL

Unknown Feb 26, 2024 • 13:10 UTC Zacks Investment Research • Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -16.67% and 4.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

BCRX RIGL